Aristotle University Of Thessaloniki (AUTH)
Ταυτοποίηση αναστολέων πρωτεϊνικών κινασών που καταστέλλουν τη βιωσιμότητα των μολυσμένων από τον ιό EBV Β λεμφοκυττάρων
Abstract
dc:descriptionEpstein-Barr virus (EBV) is a human c-herpesvirus that infects B lymphocytes as well as epithelial cells. Latent EBV infection is associated with several malignancies of B lymphocytes that include Burkitt’s lymphomas, Hodgkin’s lymphomas, AIDS-associated lymphomas, and post-transplantation lymphoproliferative disorders (PTLDs). In vitro, EBV can transform resting B cells into longterm proliferating lymphoblastoid cell lines (LCLs). LCLs display type III latency, in which a limited set of viral genes is expressed. This set includes six EBV nuclear antigens (EBNA 1, 2, 3A, 3B, 3C and-LP), three membrane proteins (LMP1, LMP2A and LMP2B), two short non-polyadenylated RNAs (EBER1 and EBER2) and transcripts from the BamHI A region of EBV (BARTs).The process of B lymphocyte transformation by EBV relies on the usurpation of cellular growth promoting and antiapoptotic signaling pathways by viral proteins. For example, LMP2A mimics and modulates the signaling pathway of B-cell antigen receptor (BCR), whereas the LMP1 oncoprotein mimics a constitutively active CD40 receptor. These signaling pathways involve a number of protein kinases, which are functionally modulated by the activity of latent EBV antigens. Extracellular signal-regulated kinases (ERKs) as well as several protein tyrosine kinases (PTKs), including those of Src family (such as Fyn, Lyn, Lck and cSrc), are some of the proteins that are activated by these EBV antigens. In an effort to identify small molecule inhibitors of the growth of EBV-transformed B lymphocytes a library of 214 kinase inhibitors was screened. This effort identified two tyrosine kinase inhibitors, PP2 and compound 5, and two MEK inhibitors, PD198306 and Cl-1040, that reduced preferentially the viability of EBV-infected human B lymphocytes and this reduction was associated with the initiation of apoptosis. Each of the four inhibitors decreased the phosphorylation of its kinase target. Moreover, the use of Lck protein specific inhibitor Α-770041, as well as Lck gene silencing experiments showed that the inhibition of Lck gene expression had a negative impact on the viability of the EBV positive cell lines, implying that Lck protein could be a possible target of PP2 and compound 5. In a similar way, silencing of MEK-1 gene negatively affected the viability of the EBV positive cell lines. These findings highlight the possible dependence of EBV-infected B lymphocytes on specific kinase-regulated pathways underlining the potential for the development of small molecule-based therapeutics that could target selectively EBV-associated human B lymphocyte malignancies.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2024
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Mavromatidis, Vasileios
- Μαυροματίδης, Βασίλειος
Subjects
dc:subject × 14- Ιός Epstein-Barr
- Βιωσιμότητα των καρκινικών Β-λεμφοκυττάρων
- Αναστολείς κινασών τυροσίνης
- Αναστολείς ΜΕΚ πρωτεϊνών
- Epstein-Barr virus (EBV)
- Cancer B-lymphocytes viability
- Tyrosine kinase inhibitors
- MEK inhibitors
- Βιολογία
- Φυσικές Επιστήμες
- Βιοχημεία και Μοριακή βιολογία
- Biological Sciences
- Natural Sciences
- Biochemistry and Molecular Biology
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/56770